Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.
Actively Recruiting
Researchers are evaluating the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for treating B-cell lymphoma. This Phase II clinical trial focuses on patients diagnosed with specific types of B-cell lymphoma, including relapsed or refractory indolent B-cell lymphoma and diffuse large B-cell lymphoma DLBCL. The study aims to assess how well this combination therapy works and its overall safety. Participants will receive TQB3702 tablets at a dose of 200 mg every 4 weeks as one treatment cycle. Alongside this, they will undergo chemotherapy cycles every 3 or 4 weeks, with a total of 6 to 12 cycles of combination therapy. The chemotherapy regimen is designed to inhibit tumor cell growth, suppress DNA synthesis, induce cancer cell death, support immune function, and prevent new blood vessel formation that supports tumors. During the trial, participants will be closely monitored for treatment response and safety. Researchers will measure overall and complete response rates up to 2 years, as well as adverse events, progression-free survival, duration of response, and overall survival up to death from any cause. The study includes assessments from baseline through combination therapy completion and follow-up periods lasting up to 2 years. This comprehensive monitoring helps understand both the immediate and longer-term effects of the treatment.
Actively Recruiting
Researchers are studying the efficacy and safety of combining LM-302 injection with tislelizumab compared to tislelizumab plus chemotherapy for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma that tests positive for CLDN18.2. This Phase III trial focuses on patients who have not been previously treated systemically for this cancer type and aims to understand if the new combination improves outcomes. Participants are randomly assigned to one of two study groups one receiving LM-302 injection with tislelizumab in 14-day treatment cycles, and the other receiving tislelizumab combined with oxaliplatin injection and capecitabine tablets in 21-day cycles. The trial is open-label, meaning both participants and researchers know which treatment is given. The study treatment period extends until disease progression or other discontinuation criteria are met. During the study, participants undergo regular assessments including imaging to measure progression-free survival, overall survival, tumor response rates, and adverse events over up to two years. Laboratory tests, tumor tissue analyses, and physical performance evaluations are conducted to monitor safety and treatment effects. Women of childbearing potential and men must use effective contraception during and after treatment. The entire study participation lasts until the primary outcome measure is reached or the study ends in May 2030.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Researchers are evaluating the use of intravenous tenecteplase for treating acute ischemic stroke when the exact time of stroke onset is unknown, such as in wake-up stroke cases. This phase 3, multicenter, randomized trial aims to determine the safety and effectiveness of tenecteplase compared to standard medical treatment using non-contrast CT for patient selection. The main goal is to assess excellent patient outcomes based on functional status 90 days after treatment. Participants will be randomly assigned to one of two groups one group receives intravenous tenecteplase at a dose of 0.25 mgkg up to 25 mg plus standard medical care, and the other group receives standard medical care alone without thrombolysis. Tenecteplase is given as a single intravenous bolus soon after randomization. Standard medical treatment includes therapies such as antiplatelets, anticoagulants, blood pressure, and cholesterol management according to local guidelines. During the study, participants will be monitored and evaluated with assessments including neurological scales, disability scores, and quality of life questionnaires at various time points up to 90 days. The primary measure is an excellent outcome based on the modified Rankin Scale at about 3 months. Safety and functional improvements will also be tracked through clinical evaluations and imaging. The entire participation lasts until the 90-day assessment after treatment.